Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dexmethylphenidate Clear all
Recruiting Phase 4 Interventional

Treating Young Children With Attention Deficit Hyperactivity Disorder

NCT07300956
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA), Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CTx-1301 Comparative Bioavailability Study

NCT04138498
View directory record Official record
Conditions
ADHD
Interventions
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

NCT03460652
View directory record Official record
Conditions
ADHD
Interventions
KP415 oral capsule
Drug
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Bradenton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 4 Interventional

Use of Focalin for Fatigue in Sarcoidosis

NCT00361387
View directory record Official record
Conditions
Sarcoidosis
Interventions
d-methylphenidate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2011 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening

NCT06000501
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
Serdexmethylphenidate/dexmethylphenidate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

NCT03292952
View directory record Official record
Conditions
ADHD
Interventions
KP415 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

NCT05286762
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions
CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00564954
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

NCT00301236
View directory record Official record
Conditions
ADHD, ADD
Interventions
Dexmethylphenidate HCl extended-release capsules
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
252 participants
Timeline
2006
U.S. locations
25
States / cities
Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

NCT00393042
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions

NCT00829712
View directory record Official record
Conditions
Healthy
Interventions
Dexmethylphenidate Hydrochloride
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)

NCT07119073
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Dexmethylphenidate
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 22, 2026, 4:41 AM EDT
Suspended Phase 3 Interventional

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

NCT05924594
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Study of SDX in Patients With Idiopathic Hypersomnia (IH)

NCT05668754
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Serdexmethylphenidate, Placebo
Drug · Other
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional

Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors

NCT00031798
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
Interventions
methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

NCT00141063
View directory record Official record
Conditions
ADHD
Interventions
Focalin XR
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

NCT04449250
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Dexmethylphenidate
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 22, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

NCT00047476
View directory record Official record
Conditions
Fatigue, Neoplasms
Interventions
dexmethylphenidate(d-mph)
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
21
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 22, 2026, 4:41 AM EDT